Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000899140-25-000852
Filing Date
2025-07-25
Accepted
2025-07-25 16:15:26
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8421
2 JOINT FILING AGREEMENT r991.htm EX-99.1 4579
  Complete submission text file 0000899140-25-000852.txt   15145
Mailing Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540
Business Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 609-375-2227
Sonnet BioTherapeutics Holdings, Inc. (Subject) CIK: 0001106838 (see all company filings)

EIN.: 522102141 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SCHEDULE 13G | Act: 34 | File No.: 005-81795 | Film No.: 251151862
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 149 5TH AVENUE 10TH FLOOR NEW YORK NY 10010
Business Address 149 5TH AVENUE 10TH FLOOR NEW YORK NY 10010 516-965-7531
Republic Digital Opportunistic Digital Assets Master Fund, Ltd. (Filed by) CIK: 0002078198 (see all company filings)

EIN.: 981662885 | State of Incorp.: E9 | Fiscal Year End: 1231
LEI: 549300KS7DFXOKEJDA98
Type: SCHEDULE 13G